Back to Search
Start Over
The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study.
- Source :
- Breast; Aug2023, Vol. 70, p56-62, 7p
- Publication Year :
- 2023
-
Abstract
- CDK4/6 inhibitors combined with endocrine therapy have significantly improved treatment outcomes for metastatic hormone receptor-positive (HR+) breast cancer patients. However, the impact of low HER2 expression on treatment response and progression-free survival (PFS) remains unclear. This multicenter retrospective study included 204 HR+ breast cancer patients treated with a combination of CDK4/6 inhibitor and endocrine therapy. HER2-zero disease was detected in 138 (68%) and HER2-low disease in 66 (32%) patients. Treatment-related characteristics and clinical outcomes were analyzed, with a median follow-up of 22 months. The objective response rate (ORR) was 72.7% in the HER2 low group and 66.6% in the HER2 zero group (p = 0.54). Median PFS was not significantly different between the HER2-low and HER2 zero groups (19 months vs.18 months, p = 0.89), although there was a trend toward longer PFS in the HER2-low group for first-line treatment (24 months progression-free survival rate 63% vs 49%). In recurrent disease, the median PFS was 25 months in the HER2-low group and 12 months in the HER2-zero group (p = 0.08), while in de novo metastatic disease, the median PFS was 18 months in the HER2-low group and 27 months in the HER2-zero group (p = 0.16). The order of CDK4/6 inhibitor use and the presence of visceral metastasis were identified as independent variables affecting PFS. Low HER2 expression did not significantly impact treatment response or PFS in HR+ breast cancer patients treated with a CDK4/6 inhibitor and endocrine therapy. Because of the conflicting results in the literature, further prospective studies are needed to evaluate the clinical significance of HER2 expression in HR+ breast cancer. • Combination therapy with CDK4/6 inhibitors and endocrine therapy achieves impressive objective response rates in metastatic hormone-positive breast cancer patients regardless of HER2 status. • Low HER2 expression did not significantly affect survival in hormone-positive metastatic breast cancer patients receiving CDK4/6 inhibitors and endocrine therapy. • The order of CDK4/6 inhibitor use and the presence of visceral metastasis were identified as independent factors influencing progression-free survival. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 09609776
- Volume :
- 70
- Database :
- Supplemental Index
- Journal :
- Breast
- Publication Type :
- Academic Journal
- Accession number :
- 164926947
- Full Text :
- https://doi.org/10.1016/j.breast.2023.06.006